CorMedix Inc. (CRMD), a biopharmaceutical company, on Tuesday announced a turnaround to profit in the fourth quarter from loss in the last year. The company recorded revenue for the quarter on sales of DefenCath and reiterated cash operating expenses for the full year.
Shares of CorMedix are dropping in the pre-market trading.
In the fourth quarter, net income came in at $13.47 million compared with net loss of $14.75 million last year.
Fourth quarter earnings per share were $0.22 versus loss of $0.26 the prior year.
Five Analysts, on average, had expected the company to report $0.14 per share. Analysts' estimates typically exclude special items.
Revenue for the quarter came in at $31.21 million for the quarter. Operating expenses for the quarter were $17.098 million, while the expenses in the prior quarter were $15.668 million a year ago.
Looking ahead, CorMedix expects preliminary net revenue for the first half of 2025 of $50 - $60 million, with more than $33 million expected in the first quarter. For 2025, the Company reiterated cash operating expense guidance of $72 - $78 million.
In the pre-market trading, CorMedix is 22.38% lesser at $8.36 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.